Biotech China 2014
Biologic Therapies Summit IV: Current Agents and Future Targets
InterContinental Hotel & Bank of America Conference Center
9801 Carnegie Ave. Cleveland, Ohio 44106
Cleveland, Ohio
http://www.clevelandclinicmeded.com/live/courses/2011/biotherapiesIV/overview.htm
The development of biologic agents has significantly improved the care of patients with autoimmune and inflammatory disorders. However, emerging patient care data, especially on side effects, have muddled the clinical practice picture. 

The Cleveland Clinic R.J. Fasenmyer Center for Clinical Immunology has a highly successful record of providing evidence-based continuing medical education activities to practitioners in rheumatology. The Center’s biannual Biologic Therapies Summits have been key venues for presenting comprehensive reviews and clinical analyses of biologic therapies. 

The Biologic Therapies Summit IV continues that successful tradition, both in terms of quality presentations and in fulfilling attendees’ educational objectives. An international faculty of experts who span a multitude of scientific disciplines will provide their insights on a variety of timely topics:
Research advances in immunodeficiencies and autoimmunity,
Approved biologic agents and clinical data,
New biologic agents being developed,
Toxicities associated with biologic agents,
Clinical implications and potential new indications.

Schedule of Presentations:

Thursday, May 5, 2011
07:00:00 Registration Continental Breakfast and Exhibits
07:55:00 SESSION I | PLENARY SESSION | IMMUNOLOGIC BREAKTHROUGHS Leonard Calabrese
08:00:00 Welcoming Remarks Leonard Calabrese
08:05:00 KEYNOTE ADDRESS | Primary Immunodeficiencies and Autoimmunity | Lessons from the Field Jean-Laurent Casanova
08:55:00 Biologic Basis of Autoinflammatory Diseases Daniel Kastner
09:40:00 Refreshment Break and Exhibits
10:20:00 Interferon in Health and Disease Mary K. Crow
11:05:00 The Evolution of Stem Cell Therapy for Autoimmune and Inflammatory Diseases Alan Tyndall
11:50:00 Lunch
12:55:00 SESSION II | APPROVED AGENTS | THE SECOND DECADE
13:00:00 Impact of Biologics on Rheumatic Diseases Paul Emery
13:30:00 TNF Inhibitors | Mechanism of Action of the Class Leonard Calabrese
14:00:00 B Cell Targeting | Current and Future Options
14:30:00 Refreshment Break and Exhibits
15:00:00 T Cell Targeting | Current and Future Options Peter Taylor
15:30:00 IL6 Targeting Arthur Kavanaugh
16:00:00 Panel Discussion and Questions
16:30:00 Adjourn
Friday, May 6, 2011
07:00:00 Registration, Continental Breakfast, and Exhibits
07:55:00 SESSION III | THE NEW AGENTS Brian Mandell
08:00:00 RA | New Targets and Therapies Peter Taylor
08:35:00 GI | New Targets and Therapies Scott E. Plevy
09:10:00 Neurologic Diseases | New Targets and Therapies
09:45:00 Refreshment Break and Exhibits
10:15:00 Small Molecules | Science and Clinical Application? Clifton O. Bingham
10:50:00 Biosimilars | Scientific and Regulatory Challenges Jonathan Kay
11:25:00 IVIG | Old Therapy, New Insights R. John Looney
12:00:00 Lunch
12:55:00 SESSION IV | CLINICAL CONTROVERSIES AND NEW INDICATIONS | Clinical Controversies and Minisymposium Current Issues in RA Edward Keystone
13:00:00 DEBATE | Nonbiologic vs Biologic DMARDS
13:05:00 EARLY and Aggressive Biologic Therapy Is the Preferred Option Paul Emery
13:30:00 Combination Nonbiologic DMARDS | A Cost- Effective Alternative in RA Is Logical Larry Moreland
14:00:00 TNF Failures | Sorting Out the Options Edward Keystone
14:30:00 Refreshment Break and Exhibits
14:55:00 CLINICAL CONTROVERSIES AND NEW INDICATIONS New Indications Christopher Ritchlin
15:00:00 Advances in the Treatment of Scleroderma Alan Tyndall
15:30:00 Sjögren’s and Biologic Therapies
16:00:00 SLE and Biologic Therapies Richard Furie
16:30:00 Psoriatic Arthritis | Revisiting the GRAPPA Guidelines Christopher Ritchlin
17:00:00 Adjourn
Saturday, May 7, 2011
07:30:00 Registration, Continental Breakfast, and Exhibits
08:25:00 SESSION V | PREDICTING TOXICITY Nizar N. Zein
08:30:00 Lessons from Granulomatous Infections Joanne L. Flynn
09:00:00 Biologics and the Liver – Is IL6 a Target of Concern? Nizar N. Zein
09:30:00 PML and Biologics – State-of-the-Art Richard M. Ransohoff
10:00:00 Refreshment Break and Exhibits
10:30:00 Paradoxical Toxicity – Lessons from Psoriasis Christopher Ritchlin
11:00:00 Update on Screening for TB – Is Gamma IFN Release the Way to Go? Steve Gordon
11:30:00 Cardiovascular Disease and Inflammation – Are Biologics Helpful or Harmful? M. Elaine Husni
12:00:00 Lunch
12:55:00 SESSION VI | CLINICAL CONTROVERSIES AND NEW INDICATIONS Caroline A Langford
13:00:00 Gout – Do Biologics Make Sense? Brian Mandell
13:30:00 Biologic Therapies for Metabolic Bone Disease – Risks and Benefits Chad Deal
14:00:00 Vasculitis – Current Practice and Biologics Caroline A Langford
14:30:00 Adjourn
4th Annual Pharma R&D Asia Congress
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.